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Abstract
Background: A single-institution experience of pulmonary metastasectomy in soft tissue sarcoma (STS) was retrospectively
reviewed. Our specific aim was to examine, whether the resection of pulmonary metastases could be curative. We also compared
overall survival (OS) of patients after complete or incomplete pulmonary resection and nonsurgical treatment.
Methods: Between 1987 and 2016, 1580 patients were treated for STS with curative intent by Soft Tissue Sarcoma Group at
Helsinki University Hospital, Finland. Three hundred forty-seven patients (22%) developed advanced disease and 130 STS
patients (9%) developed pulmonary metastases as first systemic relapse. Seventy four patients (5%) were operated for lung
metastases.
Results: Fifty-five patients (42%) had a complete and 19 (15%) incomplete resection. Fifty-six (43%) were unoperated. Median
OS after complete or incomplete metastasectomy, chemotherapy, or best supportive care was 22, 18, 8, and 5 months,
respectively. Twelve patients (9%) developed no further metastases and are alive with no evidence of disease. Disease-free
survival (DFS) for completely resected patients was 17% at 5 years. All long-term survivors had oligometastatic disease and
they underwent one to three complete metastasectomies.
Conclusions: Complete pulmonary metastasectomy in STS results in 5 years DFS in nearly one-fifth of patients. Most of these
patients are probably cured.
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1 INTRODUCTION
Soft tissue sarcomas (STS) are rare malignant neoplasms comprising approximately 1% of all cancers. Despite optimal local
treatment and satisfactory local control rates, 20% to 30% of STS patients develop metastases. The prognosis of metastatic
disease is usually poor with a median survival of 12 to 17 months,1-3 and overall 5-year survival of patients with metastatic STS
has not improved during the last decades. In the Thames Cancer Registry for 1985-1994 and 1995-2004, 5-year survival rates for
metastatic STS were only 13% and 15%, respectively.4 Few chemotherapy regimens are active in metastatic STS. Doxorubicin is
the most important chemotherapeutic agent,5 providing a median survival of only approximately 1 year.6
Solitary pulmonary metastasis and oligometastases are a common manifestation in STS. Aggressive surgical management of
pulmonary metastasis, including repeat metastasectomies, has achieved an important role in STS treatment but without level I or
II evidence.1,7-14 Approximately 25% of patients are alive 5 years after surgery of pulmonary metastases, but most studies do
not reveal whether these patients live with or without relapse.4 No randomized trials to compare survival after surgery and
nonsurgical treatment have been published.4 The population from which patients were selected for pulmonary metastasectomy
and the prognosis unresected patients are seldom reported. The percentage of patients undergoing pulmonary metastastasectomy
has reported to be between 31% and 58%.1,11,15
Surgical resection has been the recommended treatment for all STS patients presenting with metastases exclusively to the lungs
at our department since 1987. The object of the present study was to assess the proportion of long-term survivors without evidence
of disease in surgically treated patients and to compare their outcome to nonsurgically treated patients.
2 MATERIALS AND METHODS
2.1 Patients
During 1987-2016 1580 patients were treated for STS with curative intention by Soft Tissue Sarcoma Group at Helsinki University
Hospital (HUH). Twenty-two percent (347) of the patients developed systemic disease during follow-up, and 145 patients (9%) had
the first systemic relapse in lungs. Fifteen patients were excluded due to relapse during adjuvant treatment (11), primary pulmonary
sarcoma (2), or subtype (one rhabdomyosarcoma and one Ewing’s sarcoma). The remaining 130 patients were included in the
study (Figure 1), which was approved by the HUH Ethics Committee and the Ministry of Social and Health Affairs.
Demographic and clinical variables included age at diagnosis, sex, histologic type, grade, size, and location of the primary
sarcoma, therapy for the primary tumor, surgical margins, possible local recurrence, and disease-free interval (DFI). At pulmonary
relapse patients age, the number of nodules, possible symptoms, size of the largest nodule, and patient’s performance status
were collected from medical records. Surgical resection was classified as complete if all recognized disease was removed with
negative margins.
2.2 Follow-up protocol for STS patients following primary treatment with curative intention at Helsinki University Hospital
The treatment plan of new and relapsed STS patients is made at weekly meetings of the multidisciplinary team. After primary
treatment, all patients have regular follow-up. In high-grade sarcoma chest X-ray is performed every 2 months during the first 2
years, and thereafter three times annually up to 5 years. A physical examination and a magnetic resonance imaging (MRI; or
computed tomography [CT]) of the primary tumor region are performed every 6 months up to 2 years and thereafter annually up
to 5 years. In low-grade sarcoma, chest X-ray is performed every 4 months during the first 2 years, twice a year up to 4 years,
yearly up to 7 years and thereafter at 1.5 years intervals up to 10 years. A physical examination and an MRI (or a CT) of the
primary tumor region are performed yearly for 7 years and therafter at 1.5 years interval.
If pulmonary metastases are suspected, a chest CT is performed. Patients with metastases confined to lungs are recommended
metastasectomy if feasible. Preoperative assessment to exclude extrathoracic disease and to assess operative risks include
abdominal CT, MRI, or CT of primary tumor region and cardiac and pulmonary function tests (electrocardiogram, spirometry, and
diffusion capacity).
2.3 Statistical analyses
Overall survival (OS) was defined from the development of metastases, as defined by radiologic evidence of disease to death
or last follow-up. DFI was defined as the time from primary tumor resection or from the end of adjuvant treatment to metastatic
disease. In patients with pulmonary operations, disease-free survival (DFS) was defined as time from previous complete pulmonary
resection to the radiologic evidence of progression. Patients dying without relapse were censored in the analysis of DFS. Normally
distributed continuous variables were summarized using mean and standard deviation and compared using a t-test. Nonnormally
distributed variables were summarized by median and range and compared with the Wilcoxon rank-sum test. Proportions were
compared using the χ2 test. Survival data were graphically displayed as Kaplan–Meier curves. Differences between groups were
assessed by the log-rank test. All statistical tests were two-sided. IBM SPSS Statistics version 23 (SPSS, Chicago, Illinois) was
used for all analyses.
3 RESULTS
3.1 Characteristics of patients
The present study includes 130 STS patients, who developed pulmonary metastases as first systemic relapse after curative local
treatment. No patient was lost during follow-up. Patient characteristics at primary diagnosis are presented in Table 1. The median
age at diagnosis was 60 years. Median tumor size was 9 cm. All but two tumors were high grade.
3.2 Nonsurgical treatment
Thirty-six patients (64%) were treated with palliative chemotherapy and twenty patients (36%) were treated with best supportive
care (BSC) without surgery. Reasons for abstaining from surgery were insufficient performance status (19 patients), multiple
pulmonary metastases (15), difficult anatomical location of metastases (15), patient’s denial (4), short DFI (2), and disease
progression between detection and planned surgical resection (1). Doxorubin–ifosfamid was the most common first-line regimen
(16 patients) followed by single doxorubicin (six patients). No patient achieved complete response (CR), seven patients had partial
response (PR), and 19 stable diseases. Nine patients received radiation therapy (RT) for pulmonary metastases. Median OS of
the chemotherapy and BSC groups were 8 and 5 months, respectively. Five- and ten-year OS rate for chemotherapy group were
6% and 0% and for BSC 0% and 0%, respectively.
3.3 Surgical treatment
Seventy-four (57%) of the 130 patients were resected for pulmonary metastases. Fifty-two patients (70%) had open thoracotomy
as first operation, 18 (24%) were treated with video-assisted thoracoscopy (VATS). Two patients (3%) with bilateral disease had
open thoracotomy in one side and VATS on the side and in two patients (3%) VATS was transformed to open thoracotomy because
more metastases were detected than in preoperative imaging. One patient died due complications (empyema). The operated
patients were younger, with better performance status and had more often unilateral disease with fewer nodules when compared
with conservatively treated patients. Characteristics of operated and unoperated patients are shown in Table 2.
3.3.1 Incomplete resection
Nineteen patients (15%) were treated with incomplete surgery. In 11 patients CT did not show all metastases or pleural growth. In
four patients surgery was incomplete due to the central location of metastases. Tumor cell contamination during surgery occurred
in two patients (3%) and both relapsed in the lungs. Eight patients received postoperative chemotherapy after an incomplete
resection. All patients with incomplete surgery progressed. Fifteen of the 19 patients with incomplete surgery received palliative
chemotherapy for progression. Median OS after incomplete surgery was 18 months (range, 2-84 months). OS was 8.6% and 0%
at 5 and 10 years, respectively.
3.3.2 Complete resection
In 55 patients, a complete resection was achieved in the first surgery. Median OS was 22 months, (range, 6-228 months) after the
first complete resection (Figure 2A). Nine patients received adjuvant chemotherapy and of these patients, two remain relapse-
free. Forty-five (82%) patients developed a second systemic relapse after complete resection. Twenty-two (42%) patients
developed only pulmonary metastases and 12 (24%) of these were@@ re-resected. Complete resection in second surgery was
achieved in eight patients, who all relapsed. Five of these patients developed pulmonary relapse and had a third complete
resection. Two of these remain relapse-free (Figure 1). Thus, 12 patients are presently disease-free after radical surgery in 1 to 3
operations. Median follow-up time for 12 relapse-free patients was 29 months, range 8 to 105 months. DFS for completely resected
patients was 17% at 5 years (Figure 2B). All systemic recurrences occured within 5 years. Median OS after the last complete
pulmonary resection was 20 months, range 4 to 178 months. OS at 5 years was 20%.
3.4 Survival of patients
Median OS of patients with BSC, chemotherapy only, incompletely and completely resected metastases were 5, 8, 18, and 22
months, respectively, P < .0001 (Figure 3). The difference between chemotherapy treatment and incomplete surgical treatment
was not significant (P = .173).
3.5 Prognostic factors
Analyses of 55 radically resected patients revealed two statistically significant favorable prognostic factors for DFS: a single
nodule resected at last complete pulmonary resection and DFI >1.3 years (Table 3). Patients with oligometastatic disease were
the only long-term disease-free survivors (Table 3). Long-term DFS was seen, however, even after three repeated surgical
resections.
4 DISCUSSION
Favorable outcome after surgical resection of pulmonary metastases in STS have been reported in numerous studies since the
1940s.16 The true benefit of this treatment policy is still uncertain and has been seriously questioned in the absence of randomized
trials.4
Large retrospective studies from specialist centers1,7-9 and a systematic review4 have shown 5-year survival between 13% and
52% after complete resection of lung metastases. However, 5-year OS is not necessarily equal to cure due to the variable clinical
course of STS. Most previous long-term studies have reported only OS, but not the proportion of patients without evidence of
disease (NED). We found only two large1,9 and two small17,18 series of metastasectomy reporting also long-term DFS. None of
these reported estimated DFS at 5 or 10 years. Nine percent of patients remained NED at the end of follow-up in both of the two
largest studies of 7191 and 539 patients.9 Follow-up time varied between 61 to 234 months in Billingsley’s study1 but was not
reported in Chudgar’s study.9 Like in the present series (98%), the majority of patients had high-grade sarcoma, 87% and 90%,
respectively.1,9 The small series of 2017 and 23 patients,18 reported that 20% and 52% were NED, respectively, but long-term
DFS was not reported.
Long-term survival after chemotherapy of advanced STS is uncommon. In a study of 2187 patients with advanced STS, the
estimated OS at 5 years from first-line chemotherapy was 8% decreasing to 5.6% at 10 years.19 Only 3% were alive 5 years after
starting chemotherapy, 45% of these had either a complete or PR, and in these patients 10-year OS was 94%.19 In a retrospective
investigation 7% of patients with advanced STS achieved complete remission by chemotherapy alone.20 The median DFS was
23 months and seven patients (3.5%) were in continuing remission at the end of follow-up20 suggesting chemotherapy may
occasionally be curative. The efficacy of single doxorucin has been compared with combination of doxorubicin and ifosfamide in
a phase 3 study. The median follow-up of was 56 to 59 months and only 6% of patients in the doxorubicin group and 8% in the
combination arm were alive and progression-free at the cut-off date.6 Thus, long-term survival with advanced STS is possible
without cure, and a small proportion of nonsurgically treated metastatic may even be cured by chemotherapy.
In the present study 5-year survival without disease (DFS) was defined as a surrogate endpoint for cure. DFS for completely
resected patients was 17% at 5 years. OS of these patients at 5 years was 20%. Thus, about 15% of those alive at 5 years after
resection were living with disease and all these died before reaching 10 years of follow-up. Since all systemic relapses occured
within first 5 years of follow-up, the 17% proportion of patients alive after five and 10 years with no evidence of disease may
probably be considered cured by metastasectomy.
Two favorable prognostic factors for 5-year DFS after complete resection of pulmonary metastasis were identified: a single nodule
resected at last complete resection and a DFI over 1.3 years. Our results is in concordance with previous studies in which a single
pulmonary metastatic lesion,1,7,9 DFI of greater than twelve months,1,7-9 negative resection margins at metastectomy,1
histologic subtype of leiomyosarcoma,9 minimally invasive resection9 ) and younger age8 have been reported to be favorable
prognostic factors after metastasectomy. The endpoint of all these previous studies has been OS, while the present study
examined prognostic factors for long-term DFS. Although these two endpoints are naturally related, long-term OS in advanced
STS is not always equivalent to cure, due to the variable clinical course of this disease. Oligometastatic disease, in the present
series a single nodule resected at last complete resection, and up to three lesions resected at repeated surgery, was the most
important predictive factor for the chance of long-term DFS. A short DFI, while being statistically significantly associated to short
DFS, did not preclude the chance of being a long-term relapse-free survivor, as 11% of patients with complete metastatic resection
and a DFS < 1.3 years, were also long-term disease-free survivors.
As expected, patients treated with incomplete surgery, only chemotherapy or BSC, had a significantly worse outcome than patients
with complete resection. Fifty-six patients were not operated and most of them received palliative chemotherapy. If the surgery
was incomplete, the patients had no survival advantage over patients only treated with chemotherapy, although the operated
patients were younger, with better performance status and had more often unilateral disease with few nodules. There is no
evidence in the literature of palliative benefit from pulmonary metastasectomy,21 but life quality after first pulmonary resection has
been studied prospectively. Three months after the operation, patients had significantly more pain, dyspnea, fatigue and
deteriorated physical functioning compared to preoperative state.21 Thus, if it is technically impossible to perform complete
resection, our results suggest that chemotherapy should generally be preferred to surgery.
Our study has certain limitations. During 30 years time of data collection, changes occurred in the therapeutic strategies, new
drugs for sarcomas were introduced, surgical, RT, and lung imaging techniques were developed which all may influence prognosis.
Strengths of the study include a consistently written treatment protocol with the same policy of surgical resections for lung
metastases during 30 years, and complete documentation of patient demographics, tumor characteristics, follow-up for recurrence
and survival of all patients.
In conclusion, radical pulmonary metastasectomy seems to lead to permanent cure as reflected by 5-year DFS and OS in
oligometastatic patients. Patients may be cured also after repeated resections. This retrospective study indicated no advantage of
incomplete resection compared with nonsurgical treatment.
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Age at Diagnosis (years)
Median 60
Range 17-91




Lower extremity 60 (46)
Upper extremity 14 (11)
Trunk 40 (31)
Head&neck 3 (2)
Other sitesa 13 (10)


















Epithelioid sarcoma 3 (2)
Sarcoma NOS 12 (9)





Radiation therapy to primary tumour
Yes 84 (65)
No 46 (35)




Description of primary tumour, patient and treatment
characteristics of 130 patients with pulmonary
dissemination as first systemic relapse
MPNST, malignant peripheral neural sheath tumor;
NOS, not otherwise spesified; OS, osteosarcoma;
UPS, undifferentiated pleomorphic sarcoma.
aOne in testis, two in prostate, one in uterus, eight in
retroperitoneum and one intra-abdominally.
bSize was not determined in four tumours.









n = 55 n = 19 n = 36 n = 20
Disease-free interval (years)
Median 1.6 0.8 0.5 0.7 0.005
Range 0.1-10.8 0.5-4.7 0.1-3.3 0.3-7.1
Age at Systemic Relapse
Median 54 64 62 84 <0.001
Range 18-83 19-83 21-85 36-91
Laterality <0.001
Unilateral 41 9 1 8
Bilateral 14 10 35 12
No of nodules at first relapse 0.011
1 28 0 1 6
2 13 6 1 5
3 7 3 1 0
4 4 0 4 0
>4 3 4 11 1
Unknown 0 6 18 8
Symptoms 0.002
Yes 4 2 7 9
No 51 17 29 11
Largest nodule at first relapse (mm) 0.11
6-10 8 2 1 0
11-20 20 2 8 3
21-30 14 5 4 0
31-40 3 2 0 3
41-50 4 3 1 3
51-60 1 0 2 2
61-70 0 1 0 2
>70 0 1 1 0
Unknown 5 3 19 7
WHO PS <0.001
0 42 11 12 1
1 13 8 16 5
2 0 0 8 12
3 0 0 0 2
Table 2
Description of tumour, patient and treatment characteristics of 130 patients at first systemic relapse to lungs by treatment
category
PS, performance status.
aχ2 test or Fisher's exact test.
n 5y DFS (%) Pb
Age at Last Complete Pulmonary resection, years (median )
<53.9 27 18.5 0.423
>=53.9 28 11.3
Which pulmonary resection was the last complete
1st 47 14.1 0.359
2-5th 8 25.0
Disease-free interval prior to the last complete pulmonary surgery (median)
<1.3 28 10.7 0.047
>1.3 27 18.8
No of nodules removed in the last complete pulmonary resection
1 32 30.6 0.004
>1 13 0
Total no of nodules resected
1 26 36.0 0.050
2 12 0
3 7 19.0
>3 (4-15) 10 0
Laterality in the last complete pulmonary surgery
Unilateral 46 19.5 0.378
Bilateral 9 0
Surgery type in the last  complete pulmonary surgery
Thoracotomy 37 15.8 0.351
VATS 18 0
Largest nodule removed (mm)a
<20 25 28.5 0.222
>=20 25 5.3
Table 3
Disease-free survival at 5 years after the last complete pulmonary surgery for patients having complete pulmonary surgery (n =
55)
DFS, disease-free survival; VATS, video-assisted thoracoscopic surgery
aSize not reported in 5 cases.
bχ2 test or Fisher's exact test.
FIGURE 1 Flow chart of the patient population. STS, soft tissue sarcoma; VATS, video-assisted thoracoscopy
FIGURE 2 A, Overall survival after first complete metastasectomy. B, Disease-free survival after the last complete metastasectomy
FIGURE 3 Overall survival by treatment category of the 130 patients. BSC, best supportive care; CT, chemotherapy
